<?xml version='1.0' encoding='utf-8'?>
<document id="29469197"><sentence text="Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data."><entity charOffset="72-82" id="DDI-PubMed.29469197.s1.e0" text="BMS-823778" /></sentence><sentence text="Previous studies demonstrated direct correlation between CYP2C19 genotype and BMS-823778 clearance in healthy volunteers" /><sentence text=" The objective of the present study was to develop a physiologically-based pharmacokinetic (PBPK) model for BMS-823778 and use the model to predict PK and drug-drug interaction (DDI) in virtual populations with multiple polymorphic genes"><entity charOffset="108-118" id="DDI-PubMed.29469197.s3.e0" text="BMS-823778" /></sentence><sentence text="" /><sentence text="The PBPK model was built and verified using existing clinical data" /><sentence text=" The verified model was simulated to predict PK of BMS-823778 and significance of DDI with a strong CYP3A4 inhibitor in subjects with various CYP2C19 and UGT1A4 genotypes"><entity charOffset="51-61" id="DDI-PubMed.29469197.s6.e0" text="BMS-823778" /></sentence><sentence text="" /><sentence text="The verified PBPK model of BMS-823778 accurately recovered observed PK in different populations"><entity charOffset="27-37" id="DDI-PubMed.29469197.s8.e0" text="BMS-823778" /></sentence><sentence text=" In addition, the model was able to capture the exposure differences between subjects with different CYP2C19 genotypes" /><sentence text=" PK simulation indicated higher exposures of BMS-823778 in CYP2C19 poor metabolizers who were also devoid of UGT1A4 activity, compared to those with normal UGT1A4 functionality"><entity charOffset="45-55" id="DDI-PubMed.29469197.s10.e0" text="BMS-823778" /></sentence><sentence text=" Moderate DDI with itraconazole was predicted in subjects with wild-type CYP2C19 or UGT1A4"><entity charOffset="19-31" id="DDI-PubMed.29469197.s11.e0" text="itraconazole" /></sentence><sentence text=" However, in subjects without CYP2C19 or UGT1A4 functionality, significant DDI was predicted when BMS-823778 was coadministered with itraconazole"><entity charOffset="98-108" id="DDI-PubMed.29469197.s12.e0" text="BMS-823778" /><entity charOffset="133-145" id="DDI-PubMed.29469197.s12.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.29469197.s12.e0" e2="DDI-PubMed.29469197.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29469197.s12.e0" e2="DDI-PubMed.29469197.s12.e1" /></sentence><sentence text="" /><sentence text="A PBPK model was developed using clinical data that accurately predicted human PK in different population with various CYP2C19 phenotypes" /><sentence text=" Simulations with the verified PBPK model indicated that UGT1A4 was probably an important clearance pathway in CYP2C19 poor metabolizers" /><sentence text=" DDI with itraconazole is likely to be dependent on the genotypes of CYP2C19 and UGT1A4"><entity charOffset="10-22" id="DDI-PubMed.29469197.s16.e0" text="itraconazole" /></sentence><sentence text="" /></document>